##########END##########
Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes
##########END##########
However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.
##########END##########
Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment : see the manufacturers' summaries of product characteristics for details
##########END##########
Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3â€“6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.
##########END##########
Type 2 diabetes in adults : management (NG28) conditions#notice-of-rights)
##########END##########
Last updated May 2017 1 Recommendations
##########END##########
The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)
##########END##########
Initial drug treatment
##########END##########
Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)
##########END##########
First intensification of drug treatment
##########END##########
Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)
##########END##########
Second intensification of drug treatment
##########END##########
Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin
##########END##########
Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.
##########END##########
Reassess the person's needs and circumstances at each review and think about whether to stop any medicines that are not effective.
##########END##########
Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.
##########END##########
Offer structured education to adults with type 2 diabetes and/or their family members or carers (as appropriate) at and around the time of diagnosis, with
##########END##########
Type 2 diabetes in adults : management (NG28) conditions#notice-of-rights)
